retatrutide fda approval status clinical data 2026: Everything We Know So Far Retatrutide clinical trial done! Now – An experimental weight loss drug

None has yet entered Phase 3, and triple agonism remains the most-watched class in current clinical-trial publication

10.2337/dc24-S009 [DOI] [PMC free article] [PubMed] [Google Scholar] 46

Regular monitoring of these markers helps detect potential liver stress from combining retatrutide with alcohol consumption before serious damage occurs

Heart medications can significantly improve cardiovascular health, but they sometimes lead to weight gain as a side effect

Eli Lilly is awaiting an FDA decision for a new indication for Mounjaro to reduce the risk of a major adverse cardiovascular event (MACE) in patients with type 2 diabetes mellitus (T2DM)

Liraglutide | Drugs | BNF | NICE